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Age-related macular degeneration (AMD) is a retinal disease evident after the age of 50 that damages the macula in the centre of
retina. It leads to a loss of central vision with retained peripheral vision but eventual blindness occurs in many cases. The initiation
site of AMD development is Bruch’s membrane (BM) where multiple changes occur including the deposition of plasma derived
lipids, accumulation of extracellular debris, changes in cell morphology, and viability and the formation of drusen. AMDmanifests
as early and late stage; the latter involves cell proliferation and neovascularization in wet AMD. Current therapies target the later
hyperproliferative and invasive wet stage whilst none target early developmental stages of AMD. In the lipid deposition disease
atherosclerosis modified proteoglycans bind and retain apolipoproteins in the artery wall. Chemically modified trapped lipids
are immunogenic and can initiate a chronic inflammatory process manifesting as atherosclerotic plaques and subsequent artery
blockages, heart attacks, or strokes. As plasma derived lipoprotein deposits are found in BM in early AMD, it is possible that they
arise by a similar process within the macula. In this review we consider aspects of the pathological processes underlying AMDwith
a focus on the potential role of modifications to secreted proteoglycans being a cause and therefore a target for the treatment of
early AMD.
1. Introduction
Age-related macular degeneration (AMD) is an eye disease
that develops from age 50 onwards. AMDdamages the centre
of the retina, specifically the macula (Figure 1), leading to
a gradual visual decline [1]. It causes blurred and distorted
central vision that affects visual function such as reading,
driving, and face and colour recognition [2, 3]. In developed
countries AMD is a common cause of blindness in the
elderly [4]. AMD is ranked third globally, after cataracts and
glaucoma, as the main cause of blindness [5]. In Australia, at
the age of 50 and over, one in seven people are affected by
AMD due to the influence of risk factors including ageing,
smoking, and family history [6, 7]. The key site for initial
pathological changes in AMD is the retinal barrier Bruch’s
membrane (BM), which is located between the retina and the
choroidal circulation (Figure 2). BM plays crucial functional
roles in the retina including forming a physical barrier
against the invasion of new vessels, exchange of oxygen,
nutrients, and waste products between the retinal pigmented
epithelium (RPE) cells and the choriocapillaris, cell to cell
communication, and cellular differentiation, proliferation,
migration, and tissue remodelling [8, 9]. Major changes to
BM in the early stages of AMD include abnormalities of the
extracellularmatrix components proteoglycans (PGs) and the
changes can potentially increase lipoprotein to PG binding
and consequently alter BM functionality [10, 11].
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Figure 1: Diagram showing the anatomy of the eye including the
location of the macula which is part of the retina at the back of the
eye and the key site for AMD.
The early pathological features of AMD have led us
and others to hypothesize that it can be considered as
a disease similar in some aspects to atherosclerosis and
glomerulosclerosis, which involve lipid deposition [12–15].
Previous research has focused on cell degeneration in AMD
but our interest is the role of growth factors and hormones on
the synthesis and structure of PGs [16, 17]. Research to date
has generated some treatments for late stage AMD but there
has been much less investigation of potential treatments for
the early stages of AMD. The aim of this review article is to
explore the role of PGs in the early stages of AMD and their
potential as therapeutic targets for the prevention of AMD
[14, 18, 19].
2. Classification of AMD
There aremany classifications of AMD, all aimed at providing
information about the stages of disease, but to date there
is no universally accepted staging of AMD [20]. A detailed
classification is available from the Age-Related Eye Disease
Study (AREDS). Here we will use a simplified two-stage
classification: early AMD based on the presence of drusen
and indicative of early stage pathology and late AMD based
on the penetration of choroidal blood vessels into the retina
for wet AMDand geographic atrophy for dryAMD [2, 21, 22].
This allows us to focus on the pathological changes that are
associated with either early or late BM changes.
There are two types of drusen: large, soft drusen associ-
ated with early AMD [22] and small hard drusen typically
seen with increasing age and not directly related to the
development of AMD. Choroidal neovascularization (CNV)
starts from the choroidal vasculature with leaky blood vessels
breaking through BM into the RPE cell layer. CNV can result
in the leakage of blood and accumulation of serum in the eye
leading to irreversible vision loss in a short period of time
[21, 23–25] (see Figures 3 and 4).
Dry AMD, or non-CNV AMD, is also associated with
the formation of drusen. They contain lipid, proteins, and
undigested RPE waste deposited outside the RPE cell layer.
DryAMDhas three stages: early, intermediate, and advanced.
The early stage is characterised by an accumulation of
insoluble extracellular substances which later form round,
yellow, well demarcated small to medium size drusen, less
than 64𝜇mindiameter [21, 22, 26]. Geographic atrophy (GA)
denotes the late stage of dry AMD and is characterised by
a significant loss of photoreceptor cells and in many cases
involves atrophy of RPE cells within GA areas of the macula
[27]. About 65% of the patients with dry AMD can develop
wet AMD. Although wet AMD accounts for only 8% of AMD
cases, it is responsible for 85% of vision loss. Dry AMD is
considered a risk factor for wet AMD [28].
Progression of AMD shows wide variation among
patients and is characterised by many factors related to
the early signs of AMD; these include the extent of geo-
graphic atrophy, RPE abnormalities, pigment changes, and
the declining rate of the reading speed [29] as noted by
the AREDS study [30–32]. The alteration of extracellular
matrix components leads to an increased deposition of lipids
and protein components in BM. This diffuse thickening of
BM when seen in conjunction with the presence of drusen
is considered a clinical hallmark for AMD and further
abnormalities can quickly shift the disease to the CNV stage
of development [33, 34].
3. Risk Factors for AMD
AMD has other strongly associated, weakly associated, and
under-investigation risk factors [2, 6, 30, 32, 35–39]. A strong
environmental risk factor is smoking. Smokers have three
times the risk of developing AMD [2, 35]. Ageing is also a
strong risk factor with a strong increase in prevalence and
progression of AMD with age. It has been reported that the
older the patients, the later their stage of AMD. Genetic
factors indicated by family history of AMD are also a strong
risk factor with a family history of AMD predicting that a
person will have a 50% chance of developing AMD and a
particularly strong association with advanced AMD [35, 40].
Weaker risk factors for AMD include body mass index
(BMI), cardiovascular disease, hypertension and elevated
plasma fibrinogen, gender (females aremore susceptible than
males), ethnicity (light skin colour is more prone to develop
AMD), diabetes, serum lipid levels, and exposure to sunlight
(increases the risk of AMD twofold) [6, 21]. Notably for this
review there is an association betweenAMDand serum lipids
levels but relatively not much attention has been given to this
observation [41, 42]. Emerging risk factors for AMD include
diet composition, that is, vitamins, minerals, antioxidants,
and cholesterol levels, and also lifestyle factors such as alcohol
consumption, obesity, and physical activities [39, 43].There is
inconsistency in the relationship between cataracts andAMD
as some research supports a relationship and others have
found none. However there is thought to be a relationship
between AMD and hyperopia, as well as hormonal levels and
AMD [6].
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Figure 2: Diagram of the structure of the ocular fundus consisting of macula, fovea, photoreceptor cells, retinal pigmented epithelial (RPE)
cells, Bruch’s membrane, and choroidal vessels. The macula in the central retina is the key site for AMD. Two types of photoreceptors, rods
and cone outer segments, and RPE cells are affected in AMD. Bruch’s membrane consists of five layers and acts as a natural barrier enabling
the transport of nutrients and oxygen inwards and removal of waste outwards. Choroidal vessels are lined with endothelial cells and provide
the entry and exit point of nutrients and waste to the different layers of the macula.
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Figure 3: Stages of AMD: early AMD, intermediate AMD, late dry AMD, and late wet AMD. In the normal macula the arrangement of the
cells is intact, Bruch’s membrane is the normal shape and size, and all layers and tissues function correctly. In early AMD the tissue changes
begin and a thickening of Bruch’s membrane occurs. In intermediate AMD drusen (yellow circles) are clearly visible and Bruch’s membrane
functionality is impaired. In late AMD drusen are larger and more prominent (arrows) and cell atrophy and structural disorder occur. In wet
AMD blood vessels start to grow out from the choriocapillaris and enter the macula (arrows) through Bruch’s membrane.
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Figure 4: Role of growth factor mediated glycosaminoglycan
(GAG) hyperelongation in the trapping of lipids in tissues. PGs have
a basal or natural GAG chain length; however under the influence
of growth factors the GAG synthesizing mechanism is activated
leading to the increased expression of GAG elongation genes and
ultimately the secretion of PGs with elongated GAG chains. These
chains have increased binding to LDL (see text for details). Lipids
trapped in tissues undergo chemical modifications which produce
immunogens that initiate an inflammatory cascade and ultimately a
chronic inflammatory disease process.
4. Pathology of the Macula in the
Development of AMD
Theocular fundus of the eye consists of five parts, themacula,
retina, optic disc, fovea, and posterior pole, and includes BM
which is part of the choroid (see Figure 3) [7, 44]. Of the two
types of photoreceptors in the eye rod cells support vision
at low light levels and are used in the peripheral vision. On
the other hand, the cones function best in bright light and
are responsible for colour and central vision. The macula
contains far more cone photoreceptors in comparison to the
rest of the retina. Thus it plays a vital role in central vision
and acuity and enhances the resolution of details.Themacula
is the most affected part of the eye by AMD [21]. The outer
retina consists of amultilayer network of interdependent cells
and contains the retinal blood barrier which is the highest
oxygen consumer in the human body (weight to consump-
tion ratio). This retinal blood barrier has the property of
selective permeability and it is immuneprivileged [45].
Defects, damage, or disorder to BM can lead to a loss of
its functions and one of the most important is the transit
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of waste from RPE cells and photoreceptors to exit to the
choroidal blood vessels. In AMD early altered function can
be identified as a thickening of BM. Drusen formation is a
main characteristic of early AMD. Histologically drusen are
focal deposits between the basal lamina of the RPE and the
inner collagenous layer of BM [46, 47].They contain proteins,
lipoproteins, including apoB, apoE, and lipids cholesterol,
and phosphatidylcholine [47, 48]. Drusen originate from a
mixture of RPE membrane debris, active lipid release from
RPE, and some plasma lipid [45]. Nonfocal AMD laminar
deposits include BLinD and BLamD. BLinD are similar in
content and site of deposition as drusen; however they form
thin layers, are an early thickening of BM, and along with
soft drusen are more commonly found in the central macula
[49]. BLamD are found alongside BM at the RPE basal
lamina and contain cholesterol and other lipoproteins [45].
The formation of drusen happens over a period ofmany years
[7, 9, 21]. In nondiseased aged macula small drusen can exist
without significant effect [50, 51]; however numerous larger
drusen are more commonly associated with AMD [52, 53].
Other progressive features of AMD include BM thickening,
geographic and RPE atrophy, degeneration of BM and RPE,
and CNV.
Altered BM thickness and function could result from
increased lipid deposition as a consequence of positively
charged lipids and lipoproteins binding to negatively charged
PGs and thereby impacting BM function. PG-mediated
lipid deposition is a key event in early atherosclerosis and
altered PG synthesis and structure such as increased gly-
cosaminoglycan chain sulfation status and/or length result
in an increased lipoprotein to PG binding ratio and greater
deleterious lipid deposition [14, 18, 45, 54–56]. The extent to
which this occurs in AMD is still not clear. CNV is the end
result of more than 40 described pathological processes and
is the diagnostic feature of wet AMD. BM plays a vital role as
a shield or barrier against the penetration of capillary blood
vessels into the retina and the subsequent progression ofCNV
[8].
5. Molecular Pathogenesis of AMD
Based on the current understanding of AMD there are
many pathological processes that contribute to AMD at the
molecular and biochemical levels. These include oxidative
damage, abnormal lipid metabolism, apoptosis, structural
abnormalities of photoreceptor outer segments, dysfunction
of ion channels in the RPE, variations in the immune system,
and abnormalities of the extracellular matrix [45, 57, 58].
The extracellular matrix composition is varied throughout
the retina and any alteration, that is, becoming depleted,
new synthesis, or increased decomposition and waste, can
lead to AMD-related retinal changes. For example, the retina
contains high concentrations of lutein and zeaxanthin, both
macula pigments that function as antioxidant and blue light
filters that protect the retina fromphotooxidative damage and
canhalt the progression ofAMD[32, 39]. Lysis of intracellular
materialmay be converted towaste in the extracellularmatrix
[28, 43, 44, 59]. In view of the role of PGs in lipid retention
in atherosclerosis, it may prove useful to study the role of
growth factor signalling to PGs in the development of early
BM changes [60–62].
6. Proteoglycan Structure and
Alterations in AMD
Growth factors and hormones stimulate cells to cause the
elongation of glycosaminoglycan (GAG) chains on PGs
which leads to enhanced lipid binding and the trapping of
material in tissues (see Figure 4) [10, 63]. The function of
PGs varies greatly depending on the core protein family
and the type, number, size, and sulfation of GAG chains.
Generally PGs act as a binder for the extracellular matrix
as well as a pool for growth factors and tissue hydration
[63]. PGs are classified into four major families: heparan
sulfate (HS), chondroitin sulfate (CS), dermatan sulfate, and
keratan sulfate [64]. Glycosaminoglycan chains are linear
polysaccharides that are attached in variable numbers to PG
core proteins [55, 65].
PGs can be present on the cell surface and are also
secreted into the extracellular matrix of mammalian tissues
[63, 64]. Prominent PG species in the eye include the
small leucine-rich CSPGs decorin and biglycan and it is
an established paradigm that tissue insult leads to their
increased production [28, 57]. PGs are heavily sulfated and
thus negatively charged and they bind and retain positively
charged molecules including apolipoproteins on the surface
of lipids [66]. The specific role of PGs in the development
and progression of AMD has not yet been fully explored
despite their key role in extracellular matrix deposition in
the thickening of Bruch’s membrane in early AMD and
their facilitation of neovascularization in wet AMD. Bruch’s
membrane is acellular and dependent on the adjacent RPE
cells for the production of its extracellularmatrix components
including PGs which provide Bruch’s membrane with an
overall negative charge. The discontinuous nature of the
elastic lamina of Bruch’s membrane in the macula highlights
the potential of choroidal cells including endothelial, fibrob-
last, and vascular smooth muscle cells to also contribute
matrix components including PGs. In 1989 Tyl Hewitt et
al. [54] using whole eye organ cultures showed that the
proportion of newly synthesized PGs remains consistent at
75% chondroitin/dermatan sulfate (CS/DS) and 25% heparan
sulfate (HS). CS/DS GAGs are associated with collagen fibrils
in Bruch’s membrane and HS is found near the basement
membrane of RPE layer and choriocapillaris [20]. In 2012
Ambati and Fowler [21] showed that AMD extracts express
CS and HS GAGs. Total GAG content is significantly higher
in maculae containing BLamD. The relative contribution of
HSPGs and CSPGs to the pathogenesis of AMD is not well
understood.
HSPGs play vital role in AMD through regulation of the
complement system. HS is a long unbranched polysaccharide
glycosaminoglycan that is attached to ocular PG core proteins
in the extracellularmatrix of BMandmacular tissues [63, 64].
HS chains are variable in length and sulfation and it has
been shown that the quantity and sulfation of HS within
BM decrease with age [67]. This impacts the progression of
AMD because there are likely to be fewer binding sites for
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complement factor H (FH) a known risk factor for AMD
particularlywhen individuals have theY402Hpolymorphism
[68, 69]. FH negatively regulates and prevents activation of
complement.
7. Role of Growth Factors and Their
Signalling Pathways
Vasoactive growth factors are known to regulate PG synthesis
and structure; hence their signalling pathways are potential
therapeutic targets for lipid deposition diseases such as
atherosclerosis and glomerulosclerosis [70]. We know from
our studies that in vascular smooth muscle a number of
growth factors increase the synthesis of CSPGs and gly-
cosaminoglycans including platelet-derived growth factor,
vascular endothelial growth factor, transforming growth
factor beta, insulin-like growth factor, and thrombin [60–
62, 66, 71]. CSPGs via their GAG chains bind lipid and cause
lipid deposition in artery walls and promote atherosclerosis.
Currently studies are underway to investigate the contribu-
tion of these growth factors to the early stages of AMD. It
is interesting that HSPGs and sulfation are reduced with age
[67]; this suggests a reduction in lipid binding and less lipid
deposition in BM. However it is possible that, in contrast to
HSPGs, theCSPGs and their glycosaminoglycan chains could
be longer and/or more sulfated in AMD since the enzymes
that regulate the HSPGs and CSPGs chain synthesis differ
and hence the effects of different growth factors may also be
different.
8. Proteoglycan Lipid Interactions
It has been established that the extracellular matrix is very
important in controlling many biological processes that lead
to the progression of AMD. The length of endogenously
secreted GAG chains is such that increases in length produce
a large increase in the interaction between PGs and lipids
[45, 72]. Increased interactions between PGs and lipids lead
to increased accumulation of lipids in the retina [73]. One of
the most important lipids in AMD is cholesterol with high
levels of cholesterol in the lipid-rich drusen associated with
AMD. It will be beneficial to explore the possibility that these
deposits might arise by the trapping of lipids by PGs with
elongated GAG chains and the impact such interactions have
on the pathogenesis of AMD [48].
9. Conclusions
It is clear that more research into the early phase of AMD is
needed to target early changes in the macula as most works
have focused on the later stages of the disease process. Whilst
approximately 15% of cases are wet AMD, 85% of cases are
the dry form of AMD which has no available treatments.
Treatments for wet AMD do not improve dry AMD [21].
This suggests that research on early AMD might yield new
treatment targets. On the basis that there is evidence for the
accumulation of plasma derived lipids in early AMD it is
reasonable to propose that the trapping of lipids by modified
PGs might underlie the disease process in the early stages of
AMD; thus detailed studies of the metabolism of PGs by all
retinal cells are warranted in the search for a new therapeutic
target in an area in which none currently exists.
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